欧美最新另类人妖I国产成人av一区二区三区在线观看I九九热精品视频在线观看I国产精品日韩在线I激情av五月婷婷I日韩精品免费

Your Good Partner in Biology Research

  1. Home
  2. 抗體
  3. 科研級生物類似抗體
  4. VSIG4 (EU-103 Biosimilar) Recombinant Monoclonal Antibody

VSIG4 (EU-103 Biosimilar) Recombinant Monoclonal Antibody

  • 貨號：
    CSB-RA896869MB2HU
  • 規格：
    ￥83486
  • 其他：

產品詳情

  • 產品描述：
    VSIG4(EU-103 Biosimilar Antibody)重組單克隆抗體是一種用于科研領域的生物制劑，其研發旨在為相關研究提供高質量的工具。該抗體針對VSIG4靶點設計，通過重組DNA技術在實驗室環境中制備而成，具有高度的特異性和結合活性。 在科研應用中，VSIG4重組單克隆抗體可用于多種實驗場景，包括但不限于細胞水平的蛋白表達檢測分析以及組織切片的研究等。其高純度和批次間的一致性有助于確保實驗結果的可靠性與可重復性，為研究人員提供穩定的實驗條件。 該抗體的制備過程嚴格遵循生物制藥級別的質量控制標準，從基因克隆、細胞培養到蛋白純化均采用規范化流程，以保證最終產品的生物活性和結構完整性。通過特異性識別VSIG4蛋白，該抗體能夠幫助科研人員深入探究VSIG4在免疫調節、炎癥反應、腫瘤微環境等生理及病理過程中的作用機制。 作為科研工具，VSIG4重組單克隆抗體為免疫學、細胞生物學及相關疾病研究領域提供了重要支持，有助于推動對VSIG4靶點功能的深入理解，為后續的基礎研究和藥物開發奠定實驗基礎。其應用范圍覆蓋基礎實驗室研究、疾病模型構建以及藥物靶點驗證等多個科研環節，是相關領域研究中不可或缺的實驗試劑之一。
  • Uniprot No.：
  • 基因名：
  • 別名：
    Anti-VSIG4 antibody(Eutilex) research-grade biosimilar; Anti-VSIG4 antibody Eutilex research-grade biosimilar; EU 103 research-grade biosimilar; EU-103 research-grade biosimilar ;VSIG4 antibody; CRIg antibody; Z39IG antibody; UNQ317/PRO362 antibody; V-set and immunoglobulin domain-containing protein 4 antibody; Protein Z39Ig antibody
  • 反應種屬：
    Human
  • 免疫原：
    Recombinant Human VSIG4 protein
  • 免疫原種屬：
    Homo sapiens (Human)
  • 標記方式：
    Non-conjugated
  • 克隆類型：
    Monoclonal
  • 濃度：
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液：
    0.01M PBS，pH7.4
  • 產品提供形式：
    Liquid
  • 應用說明：
    Validation Status
    Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
    Guaranteed Quality
    ① Antibody purity?> 95% tested by SDS-PAGE.
    ② Endotoxin level < 0.1EU/ug tested by LAL method.
  • 儲存條件：
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期：
    3-4 weeks
  • 用途：
    It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

產品評價

靶點詳情

  • 功能：
    Phagocytic receptor, strong negative regulator of T-cell proliferation and IL2 production. Potent inhibitor of the alternative complement pathway convertases.
  • 基因功能參考文獻：
    1. Soluble VSIG4 levels are associated with the progression and recurrence of ovarian cancer, indicating that soluble VSIG4 may be used as a potential biomarker for predicting tumor prognosis. PMID: 28498255
    2. VSIG4 signaling provides an anti-immune evasion mechanism that prevents the outgrowth of intracellular bacteria in macrophages PMID: 27440002
    3. The VSIG4 upregulation by LMP1 was regulated at the transcriptional level via the NF-kB signaling axis. PMID: 28859984
    4. VSIG4 expression is significantly upregulated in human masticatory mucosa during wound healing PMID: 28005267
    5. we concluded that let-7g-5p inhibits epithelial-mesenchymal transition (EMT) consistent with reduction of glioma stem cell (GSC) phenotypes by targeting VSIG4 in glioblastoma. PMID: 27634309
    6. Data indicate that rotein kinase calpha (PKCalpha) plays a role in downregulating complement receptor Ig (CRIg coded by V-set and Ig domain-containing protein 4 VSIG4) expression. PMID: 25687755
    7. complement receptor of the immunoglobulin superfamily-L-factor H protects glomerular mesangial cells from complement-mediated injury and proliferative lesions PMID: 25114177
    8. we identified VSIG4 as a potential diagnostic marker of severe preeclampsia. The determination of this gene may improve the prognostic assessment of severe preeclampsia. PMID: 24349325
    9. Data indicate that massive V-set and Ig domain-containing 4 VSIG4(+) cell infiltration throughout the non-small-cell lung cancer samples. PMID: 24862966
    10. we showed that a complement receptor of the Ig superfamily (CRIg, also known as Z39Ig), a receptor for complement fragments (C3b and iC3b), was expressed on a subset of intestinal macrophages in murine and human large intestine PMID: 21768202
    11. These results suggest that T cells can opposite T cell hyporesponsiveness through dampening Z39Ig inhibitory signals from macrophages and thus maintain their anti-viral function in chronic hepatitis B. PMID: 20399148
    12. hVSIG4 recombinant adenovirus-transfected DCs suppress T cell proliferation, cytokine production and activation marker expression with PMID: 19914289
    13. Results report the identification and characterization of a Complement Receptor of the Immunoglobulin superfamily, CRIg, that binds complement fragments C3b and iC3b. PMID: 16530040
    14. These data indicate that the macrophage Z39Ig is involved in the pathogenesis of inflammatory diseases through chemokine induction, which will promote the migration of inflammatory cells into the lesion area, and MMP-9 induction. PMID: 16882875
    15. The specific expression of VSIG4 on resting macrophages suggests that VSIG4 may be important for the maintenance of T cell unresponsiveness in healthy tissues. PMID: 17016562
    16. CRIg is not only a phagocytic receptor, but also a potent inhibitor of the alternative pathway convertases PMID: 17051150

    顯示更多

    收起更多

  • 亞細胞定位：
    Membrane; Single-pass type I membrane protein.
  • 組織特異性：
    Abundantly expressed in several fetal tissues. In adult tissues, highest expression in lung and placenta. Expressed in resting macrophages.
  • 數據庫鏈接：

    HGNC: 17032

    OMIM: 300353

    KEGG: hsa:11326

    STRING: 9606.ENSP00000363869

    UniGene: Hs.8904



×
生命科學計算平臺